ANGLE plc, a revolutionary liquid biopsy company, is pleased to welcome Dr. Joseph (Joe) Eid to its board of Non-Executive Directors. Dr. Eid’s appointment will be effective from 19 January 2023 and will bring a wealth of experience and knowledge to the company. His expertise in the field of biotechnology will be an invaluable asset to ANGLE as it continues to develop and expand its liquid biopsy technology.
Joe is an experienced and highly qualified physician with a board certification in medical oncology, haematology, and internal medicine. With over 25 years of expertise in people and portfolio management, Joe has successfully designed and implemented clinical development, medical affairs and life cycle management plans for a range of pharmaceutical products, including cytotoxic agents, monoclonal antibodies, immuno-oncology agents, antibody-drug conjugates and CAR-T Cell therapies. His impressive career has seen him plan and execute Phase I to IV clinical trials, as well as build and manage clinical and medical affairs teams and strategies.
Joe has a wealth of experience in clinical development and medical affairs, having held senior positions at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche. Most recently, he served as Chief Medical Officer and Head of Global Drug Development for Luzsana Biotechnology, a subsidiary of Jiangsu Hengrui Pharmaceutical based in Princeton, New Jersey. His expertise will be invaluable in helping to drive the company’s growth and development.
At Merck, Joe drove the worldwide launch of Keytruda, from planning clinical trials and obtaining regulatory approval to manufacturing and developing a new PD-L1 biomarker strategy. Thanks to his leadership, the first-in-class anti-PD-1 BLA filing and approval in the US was a success.
Joseph Eid M.D., commented:
I am excited to leverage my extensive experience in developing and utilizing biomarkers in oncology to drive ANGLE’s strategy forward, and to make use of my network of pharma industry, clinical and academic thought leaders to expedite the Company’s commercial progress. I am confident that ANGLE’s Parsortix technology and liquid biopsy approach have tremendous potential in the field of oncology drug development and in clinical settings.
ANGLE Chairman, Garth Selvey, added:
We are thrilled to welcome Joe to the ANGLE Board, as his expertise and experience in oncology drug development and the use of biomarkers in clinical trials and companion diagnostics will be an invaluable asset to the Company’s pharma services business. Joe’s knowledge and insight will be of great benefit as we move forward.
In accordance with AIM Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies, there is nothing else to be revealed about Joseph Emile Eid, aged 55, apart from what has already been disclosed.